LHRH conjugated gold nanoparticles assisted efficient ovarian cancer targeting evaluated <i>via</i> spectral photon-counting CT imaging: a proof-of-concept research

Kumar, Dhiraj; Moghiseh, Mahdieh; Chitcholtan, Kenny; Mutreja, Isha; Lowe, Chiara; Butler, Anthony; Sykes, Peter; Anderson, Nigel G.; Raja, Aamir

doi:10.1039/d2tb02416k

Cited by 9 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, a study described higher uptake of 18 and 80 nm ''as prepared'' AuNPs in ovarian cancer cells (OVCAR5 and SKOV3), and selective targeting of ovarian cancer in an in vivo model using LHRH peptide-conjugated (PEG-peptide mixed monolayer) AuNPs. 66,67 Another study also showed the accumulation of 15 nm AuNPs at the periphery of Lewis lung carcinoma implanted in mice. These studies highlight the importance of SPCCT for the detection and quantification of AuNPs in cancerous cells and tissues both in vitro and in vivo.…”

Section: Gold (79) Nanoparticlesmentioning

confidence: 97%

High atomic number nanoparticles to enhance spectral CT imaging aspects

Mutreja,

Maalej,

Kaushik

et al. 2023

Mater. Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Gold (79) Nanoparticlesmentioning

confidence: 97%

High atomic number nanoparticles to enhance spectral CT imaging aspects

Mutreja,

Maalej,

Kaushik

et al. 2023

Mater. Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the context of ovarian cancer diagnosis, gold nanoformulations could be used not only as a selective drug delivery agent but also as a diagnostic tool for imaging technologies, promoting non-invasive and real-time monitoring. For instance, a recent work tested GnRH-conjugated gold nanoparticles in a mouse model of ovarian cancer to assess their use in multi-energy spectral photon-counting computed tomography ( 116 ). The authors evidenced a preferential uptake of GnRH-gold nanoparticles in organs of the abdominal cavity, suggesting that this technology has potential use for imaging of ovarian cancer.…”

Section: Gnrh-based Nano-formulations In Prostatic and Ovarian Cancermentioning

confidence: 99%

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

et al. 2023

View full text Add to dashboard Cite

For many years, luteinizing hormone-releasing hormone or gonadotropin-releasing hormone (GnRH) analogs have been used to treat androgen or estrogen-dependent tumors. However, emerging evidence shows that the GnRH receptor (GnRH-R) is overexpressed in several cancer cells, including ovarian, endometrial, and prostate cancer cells, suggesting that GnRH analogs could exert direct antitumoral actions in tumoral tissues that express GnRH-R. Another recent approach based on this knowledge was the use of GnRH peptides for developing specific targeted therapies, improving the delivery and accumulation of drugs in tumoral cells, and decreasing most side effects of current treatments. In this review, we discuss the conventional uses of GnRH analogs, together with the recent advances in GnRH-based drug delivery for ovarian, breast, and prostatic cancer cells.

show abstract

“…However, their cellular targeting levels are limited, which limits the toxic effects of drugs (68). LHRH peptidemediated multifunctional nanomaterials targeting tumors could significantly improve drug delivery and therapeutic efficacy against drug-resistant cancers (69). Pan and colleagues (53) found in a paclitaxel-resistant ST30 cell model that LHRH peptide targeting prolonged drug circulation and enhanced cytotoxicity compared to untargeted nano-delivery vehicles (IC50:3160nM vs 1285nM).…”

Section: Targeted Lhrh Peptide Receptor Therapymentioning

confidence: 99%

Peptides for diagnosis and treatment of ovarian cancer

Guo

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Ovarian cancer is the most deadly gynecologic malignancy, and its incidence is gradually increasing. Despite improvements after treatment, the results are unsatisfactory and survival rates are relatively low. Therefore, early diagnosis and effective treatment remain two major challenges. Peptides have received significant attention in the search for new diagnostic and therapeutic approaches. Radiolabeled peptides specifically bind to cancer cell surface receptors for diagnostic purposes, while differential peptides in bodily fluids can also be used as new diagnostic markers. In terms of treatment, peptides can exert cytotoxic effects directly or act as ligands for targeted drug delivery. Peptide-based vaccines are an effective approach for tumor immunotherapy and have achieved clinical benefit. In addition, several advantages of peptides, such as specific targeting, low immunogenicity, ease of synthesis and high biosafety, make peptides attractive alternative tools for the diagnosis and treatment of cancer, particularly ovarian cancer. In this review, we focus on the recent research progress regarding peptides in the diagnosis and treatment of ovarian cancer, and their potential applications in the clinical setting.

show abstract

LHRH conjugated gold nanoparticles assisted efficient ovarian cancer targeting evaluated via spectral photon-counting CT imaging: a proof-of-concept research

Abstract: Emerging multifunctional nanoparticulate formulations take advantage of nano-meter scale size and surface chemistry to work as a therapeutic delivery agent and a diagnostic tool for non-invasive real-time monitoring using imaging...

Cited by 9 publications

References 72 publications

High atomic number nanoparticles to enhance spectral CT imaging aspects

High atomic number nanoparticles to enhance spectral CT imaging aspects

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

Peptides for diagnosis and treatment of ovarian cancer

Contact Info

Product

Resources

About